RxDoctor Payments Data

Douglas Prisco, MD

Pulmonary Disease · Mission Hills, CANPI 1154537058

Payments from drug & device makers

$6,696in general payments, 2019–2025

Across 80 payments — averaging $83.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • GSK$452
  • Mylan Specialty L.p.$395
  • Novo Nordisk$307
  • Merck$188
  • Siemens Medical Solutions USA, Inc.$129
  • plus $491 from 11 others

What the payments were for

  • Travel & lodging$3625%
  • Food & beverage$1,81927%
  • Education$4,51567%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,696 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$100,043
Medicare patients
215
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter184$166,743
Breo ElliptaFluticasone/Vilanterol197$114,040
Spiriva HandihalerTiotropium Bromide50$36,444
Spiriva RespimatTiotropium Bromide23$19,002
SymbicortBudesonide/Formoterol Fumarate56$17,087
BreynaBudesonide/Formoterol Fumarate68$16,259
Fluticasone-SalmeterolFluticasone Propion/Salmeterol65$15,328
DuleraMometasone/Formoterol35$15,041
Wixela InhubFluticasone Propion/Salmeterol84$14,593
Incruse ElliptaUmeclidinium Bromide25$12,943
Albuterol Sulfate HfaAlbuterol Sulfate408$12,308
Qvar RedihalerBeclomethasone Dipropionate35$10,312
Advair HfaFluticasone Propion/Salmeterol14$8,331
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,929
Fluticasone-VilanterolFluticasone/Vilanterol13$6,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$452$304,971434 claims
AstraZenecaSymbicort$15$17,08756 claims
MerckDulera$188$15,04135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →